Kevin Cureton - Dec 27, 2023 Form 4 Insider Report for NANOPHASE TECHNOLOGIES Corp (NANX)

Role
Chief Operating Officer
Signature
/s/ Jess Jankowski under UPA for Kevin Cureton
Stock symbol
NANX
Transactions as of
Dec 27, 2023
Transactions value $
$7,686
Form type
4
Date filed
12/29/2023, 04:00 PM
Previous filing
Jun 5, 2023
Next filing
Jan 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NANX Common Stock 101K Dec 27, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NANX Common Stock (right to purchase) Award $7.69K +12.6K $0.61 12.6K Dec 27, 2023 Common Stock 12.6K $0.61 Direct F1
holding NANX Common Stock (right to purchase) 25K Dec 27, 2023 Common Stock 25K $0.52 Direct F1, F2
holding NANX Common Stock (right to purchase) 50K Dec 27, 2023 Common Stock 50K $0.44 Direct F1
holding NANX Common Stock (right to purchase) 43.5K Dec 27, 2023 Common Stock 43.5K $0.42 Direct F1
holding NANX Common Stock (right to purchase) 50K Dec 27, 2023 Common Stock 50K $0.68 Direct F1
holding NANX Common Stock (right to purchase) 80K Dec 27, 2023 Common Stock 80K $0.82 Direct F1
holding NANX Common Stock (right to purchase) 16.5K Dec 27, 2023 Common Stock 16.5K $0.51 Direct F1
holding NANX Common Stock (right to purchase) 90K Dec 27, 2023 Common Stock 90K $0.45 Direct F1
holding NANX Common Stock (right to purchase) 90K Dec 27, 2023 Common Stock 90K $4.17 Direct F1
holding NANX Common Stock (right to purchase) 72K Dec 27, 2023 Common Stock 72K $1.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
F2 Following the recently reported exercise of 12,393 shares (11/24/21), and the 2nd exercise of 12,607 shares (11/26/21, reported above) this line item represents the 3rd exercise, of 25,000 shares of the total initial grant of 75,000 shares, leaving a balance of 25,000 shares remaining relating to this grant.